– USA, PA – Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Anne M. Phillips, M.D. has been appointed to Trevena’s Board of Directors. Dr. Phillips replaces Farah Champsi, managing director at Alta Partners, who is stepping down from the Board following the Company’s initial public offering earlier this year.
“Anne’s rich experience leading late stage clinical development and approval of important novel medicines is a wonderful addition to our Board of Directors,” said Maxine Gowen, Ph.D., chief executive officer. “She has demonstrated exceptional leadership in creating value through robust clinical development and we look forward to the perspective she will bring to our programs. We also thank Farah for her invaluable support and guidance as one of Trevena’s founding investors.”
“Trevena has demonstrated remarkable productivity in translating scientific discoveries into promising product candidates targeting important unmet medical needs,” said Dr. Phillips. “I welcome the opportunity to work with the Board of Directors and the management team to maximize the value of Trevena’s innovative and promising pipeline.”
Dr. Phillips currently is Senior Vice President of Clinical, Medical and Regulatory Affairs at Novo Nordisk Inc., where she has served since 2011. Previously, she served as a Vice President in various positions at GlaxoSmithKline, which she joined in 1998, and prior to this Dr. Phillips was Head of the Infectious Diseases Program and Deputy Physician-in-Chief at Wellesley Central Hospital/St. Michael’s Hospital in Toronto. She is a Fellow of The Royal College of Physicians and Surgeons of Canada, earned an M.D. from the University of Toronto and received a B.Sc. from the University of Western Ontario.
About Trevena
Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena is developing four biased ligand product candidates it has identified – TRV027 to treat acute heart failure (Phase 2b), TRV130 to treat moderate to severe acute pain intravenously (Phase 2b), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for treatment-refractory migraine (Preclinical).
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
